MAPT and Alzheimer disease: From the measurable p-tau species, plasma p-tau231 appears to be increased earlier in the AD continuum than others [15], yet recent developments in the field focus more on targeting the p-tau217 epitope, which provides better diagnostic accuracies, has higher median-fold changes, and is more accessible [24].